Reviewed by Michael Gill, B. Sc.
25 Ra Clinical Trials Near Me
Top Hospitals for Ra Clinical Trials
Image of Altoona Center for Clinical Research in Pennsylvania.
Altoona Center for Clinical Research
Duncansville
8Active Trials
0All Time Trials for Ra
2006First Ra Trial
Image of Desert Medical Advances in California.
Desert Medical Advances
Palm Desert
5Active Trials
0All Time Trials for Ra
2014First Ra Trial
Top Cities for Ra Clinical Trials
Ra Clinical Trials by Phase of Trial
Phase 1 Ra Clinical Trials
10Active Ra Clinical Trials
10Number of Unique Treatments
57Number of Active Locations
MultiSpectral Imaging SystemJNJ-67484703Sofusa DoseConnectCohort 1Cohort IIIPioglitazoneIA-140692 million hMSC/kg
Ra Clinical Trials by Age Group
18+ Ra Clinical Trials
84Active Ra Clinical Trials
RA Medication summary guide and RA ChoiceMultiSpectral Imaging SystemUpadacitinibJNJ-67484703MBSR treatmentActive stimulation QIDSofusa DoseConnectSerial Biopsy
Most Recent Ra Clinical Trials
Top Treatments for Ra Clinical Trials
Treatment Name
Active Ra Clinical Trials
All Time Trials for Ra
First Recorded Ra Trial
Upadacitinib
4
4
2015
Baricitinib
2
2
2019
Abatacept
2
2
2019
Filgotinib
2
2
2014
RA Medication summary guide and RA Choice
1
1
2022

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 26th, 2021

Last Reviewed: November 28th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, Jordan JM, Katz JN, Kremers HM, Wolfe F; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008 Jan;58(1):26-35. doi: 10.1002/art.23176. https://pubmed.ncbi.nlm.nih.gov/181634972 Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep;62(9):2569-81. doi: 10.1002/art.27584. https://pubmed.ncbi.nlm.nih.gov/208725953 Lorig K, Chastain RL, Ung E, Shoor S, Holman HR. Development and evaluation of a scale to measure perceived self-efficacy in people with arthritis. Arthritis Rheum. 1989 Jan;32(1):37-44. https://pubmed.ncbi.nlm.nih.gov/29124634 Yamaoka K, Tanaka Y, Kameda H, Khan N, Sasaki N, Harigai M, Song Y, Zhang Y, Takeuchi T. The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan. Drug Saf. 2021 Jun;44(6):711-722. doi: 10.1007/s40264-021-01067-x. Epub 2021 May 27. https://pubmed.ncbi.nlm.nih.gov/340417025 Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003 Mar 11;107(9):1303-7. https://pubmed.ncbi.nlm.nih.gov/126289526 Takarada Y, Takazawa H, Sato Y, Takebayashi S, Tanaka Y, Ishii N. Effects of resistance exercise combined with moderate vascular occlusion on muscular function in humans. J Appl Physiol (1985). 2000 Jun;88(6):2097-106. https://pubmed.ncbi.nlm.nih.gov/108460237 Combe B, Besuyen R, Gómez-Centeno A, Matsubara T, Sancho Jimenez JJ, Yin Z, Buch MH. Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis. Rheumatol Ther. 2022 Oct 7. doi: 10.1007/s40744-022-00494-1. [Epub ahead of print] https://pubmed.ncbi.nlm.nih.gov/362059108 Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003 Mar 11;107(9):1303-7. https://pubmed.ncbi.nlm.nih.gov/126289529 Nader A, Mohamed MF, Winzenborg I, Doelger E, Noertersheuser P, Pangan AL, Othman AA. Exposure-Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit-Risk Assessment in Rheumatoid Arthritis. Clin Pharmacol Ther. 2020 Apr;107(4):994-1003. doi: 10.1002/cpt.1671. Epub 2019 Nov 30. https://pubmed.ncbi.nlm.nih.gov/3161002110 Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998 May;41(5):778-99. https://pubmed.ncbi.nlm.nih.gov/9588729